Pfizer Inc. (NYSE:PFE) – Research analysts at Jefferies Group lifted their FY2018 earnings per share estimates for Pfizer in a research note issued on Tuesday. Jefferies Group analyst J. Holford now anticipates that the biopharmaceutical company will post earnings per share of $2.90 for the year, up from their previous estimate of $2.77. Jefferies Group has a “Neutral” rating and a $40.00 price objective on the stock.

Other equities research analysts also recently issued reports about the stock. UBS Group set a $38.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday, November 1st. JPMorgan Chase & Co. set a $39.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday, November 1st. Barclays set a $38.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday, October 11th. BMO Capital Markets set a $37.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Tuesday, October 10th. Finally, ValuEngine raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $38.94.

Shares of Pfizer (NYSE PFE) traded down $0.21 on Thursday, reaching $36.97. 10,520,000 shares of the company were exchanged, compared to its average volume of 16,330,000. The stock has a market capitalization of $220,370.00, a P/E ratio of 22.68, a P/E/G ratio of 2.45 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. Pfizer has a 1-year low of $30.90 and a 1-year high of $37.37.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The firm had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. During the same period in the prior year, the firm posted $0.61 earnings per share. The company’s revenue for the quarter was up .9% on a year-over-year basis.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be paid a dividend of $0.34 per share. The ex-dividend date is Thursday, February 1st. This is an increase from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 annualized dividend and a dividend yield of 3.68%. Pfizer’s dividend payout ratio (DPR) is 78.53%.

Pfizer announced that its board has authorized a stock repurchase plan on Monday, December 18th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to buy shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its stock is undervalued.

In other Pfizer news, insider Alexander R. Mackenzie sold 6,750 shares of Pfizer stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $37.00, for a total transaction of $249,750.00. Following the transaction, the insider now directly owns 103,458 shares of the company’s stock, valued at $3,827,946. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Alexander R. Mackenzie sold 14,700 shares of Pfizer stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total transaction of $518,910.00. Following the transaction, the insider now directly owns 117,432 shares in the company, valued at $4,145,349.60. The disclosure for this sale can be found here. Insiders have sold 29,450 shares of company stock worth $1,065,220 over the last three months. Insiders own 0.06% of the company’s stock.

Several institutional investors have recently modified their holdings of PFE. First Command Bank grew its holdings in shares of Pfizer by 131.5% in the second quarter. First Command Bank now owns 23,934 shares of the biopharmaceutical company’s stock worth $804,000 after purchasing an additional 13,596 shares during the last quarter. Stock Yards Bank & Trust Co. grew its holdings in shares of Pfizer by 0.7% in the second quarter. Stock Yards Bank & Trust Co. now owns 123,800 shares of the biopharmaceutical company’s stock worth $4,159,000 after purchasing an additional 832 shares during the last quarter. Factory Mutual Insurance Co. grew its holdings in shares of Pfizer by 2.1% in the second quarter. Factory Mutual Insurance Co. now owns 2,935,897 shares of the biopharmaceutical company’s stock worth $98,617,000 after purchasing an additional 60,000 shares during the last quarter. Prentiss Smith & Co. Inc. grew its holdings in shares of Pfizer by 4.0% in the second quarter. Prentiss Smith & Co. Inc. now owns 15,548 shares of the biopharmaceutical company’s stock worth $522,000 after purchasing an additional 600 shares during the last quarter. Finally, Capstone Asset Management Co. grew its holdings in shares of Pfizer by 79.4% in the second quarter. Capstone Asset Management Co. now owns 342,493 shares of the biopharmaceutical company’s stock worth $11,504,000 after purchasing an additional 151,626 shares during the last quarter. Hedge funds and other institutional investors own 69.75% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Analysts Issue Forecasts for Pfizer Inc.’s FY2018 Earnings (PFE)” was first published by Watch List News and is owned by of Watch List News. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/analysts-issue-forecasts-for-pfizer-inc-s-fy2018-earnings-pfe/1812468.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Earnings History and Estimates for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.